



Pressrelease 2007-04-16

## **Very good clinical results for Paclical®.**

**The pharmaceutical company Oasmia Pharmaceutical has recently concluded a phase I/II study on cancer patients with its product Paclical®. The purpose was investigation of different doses and side-effects. The results fulfilled all the company's expectations.**

Cancer is one of the most common diseases. WHO reports that 11 million people are diagnosed with cancer each year. There is a constant need for new drugs and treatments. Oasmia develops pharmaceuticals and opens up for new methods in cancer treatment.

During the recent years, Oasmia have carried out a study on cancer patients. The results will be presented shortly.

The company will initiate Phase III-studies on patients starting the third quarter 2007.

*Oasmia Pharmaceutical (publ) is a pharmaceutical company based on the latest concepts in bio-organic chemistry. The company idea is to improve treatment of serious conditions, with a focus on oncology. This is done through development of semi-synthesised substances to a new generation of effective pharmaceuticals for various areas of therapy. Oasmia is noted on the NGM Nordic MTF*

*More information is available at [www.ngm.se](http://www.ngm.se) or at [www.oasmia.com](http://www.oasmia.com).*

*For more information, contact [info@oasmia.com](mailto:info@oasmia.com) or call +46 18 50 54 40.*